Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Prophylactic treatment of breast implants with a solution of gentamicin, vancomycin and cefazolin antibiotics for women undergoing breast reconstructive surgery: protocol for a randomised, double-blind, placebo-controlled trial (The BREAST-AB trial)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Study on Hamstring Re-injury Prevention (SHARP): protocol for an international multicentre, randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association between infections and functional somatic disorders: a cross-sectional population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. APMIS 2022 focus issue on human microbiome in disease and pathology

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Prevalence of biofilms in acute infections challenges a longstanding paradigm

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fat Grafting With Expanded Adipose-Derived Stromal Cells for Breast Augmentation: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Periprosthetic infection is one of the most severe complications following implant-based breast reconstruction affecting 5%-10% of the women. Currently, many surgeons apply antibiotics locally on the breast implant to reduce the risk of postoperative infection, but no randomised, placebo-controlled trials have tested the treatment's efficacy.

METHODS AND ANALYSIS: The BREAST-AB trial (BREAST-AntiBiotics) is an investigator-initiated, multicentre, randomised, placebo-controlled, double-blind trial of local treatment with gentamicin, vancomycin and cefazolin on breast implants in women undergoing implant-based breast reconstruction. The trial drug consists of 80 mg gentamicin, 1 g vancomycin and 1 g cefazolin dissolved in 500 mL of isotonic saline. The placebo solution consists of 500 mL isotonic saline. The trial drug is used to wash the dissected tissue pocket and the breast implant prior to insertion. The primary outcome is all-cause explantation of the breast implant within 180 days after the breast reconstruction surgery. This excludes cases where the implant is replaced with a new permanent implant, for example, for cosmetic reasons. Key long-term outcomes include capsular contracture and quality of life. The trial started on 26 January 2021 and is currently recruiting.

ETHICS AND DISSEMINATION: The trial was approved by the Regional Ethics Committee of the Capital Region (H-20056592) on 1 January 2021 and the Danish Medicines Agency (2020070016) on 2 August 2020. The main paper will include the primary and secondary outcomes and will be submitted to an international peer-reviewed journal.


Original languageEnglish
Article numbere058697
JournalBMJ Open
Issue number9
Pages (from-to)e058697
Publication statusPublished - 17 Sep 2022

Bibliographical note

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

    Research areas

  • Anti-Bacterial Agents/therapeutic use, Breast Implants/adverse effects, Cefazolin/therapeutic use, Female, Gentamicins/therapeutic use, Humans, Mammaplasty, Quality of Life, Randomized Controlled Trials as Topic, Vancomycin/therapeutic use

ID: 84666371